GSK356278

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Depressive Disorder and Anxiety DisordersHuntington Disease

Phase 1

First Time in Human Study

CompletedNCT01031186

GlaxoSmithKlineDepressive Disorder and Anxiety Disorders

Start: 2009-11-23End: 2010-04-07Updated: 2017-07-27

A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278

CompletedNCT01573819

GlaxoSmithKlineHuntington Disease

Start: 2011-11-24End: 2012-04-02Updated: 2017-06-15

Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease

CompletedNCT01602900

GlaxoSmithKlineHuntington Disease

Start: 2011-11-22End: 2012-04-12Updated: 2017-06-20